{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:29Z","timestamp":1793386469329,"version":"4.5.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many patients with Alzheimer\u2019s disease (AD) are physically frail or have substantial functional impairments. There is growing evidence that such patients are at higher risk for medication-induced adverse events. Furthermore, frailty seems to be more predictive of poor clinical outcomes than chronological age alone. To our knowledge, no systematic review of clinical trials examining drug therapy of AD or behavioural and psychological symptoms of dementia (BPSD) has specifically focused on the topic of physical frailty. Our objective was to evaluate the efficacy and safety of pharmacotherapy in AD patients with frailty or significant functional impairments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic literature search in MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials (RCTs) of drug therapy of AD and BPSD in patients with significant functional impairments according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and Cochrane research criteria. Significant functionally impaired patient populations were identified using the recommendations of the Medication and Quality of Life in frail older persons (MedQoL) Research Group. Screening, selection of studies, data extraction and risk of bias assessment were performed independently by two reviewers. Outcomes including functional status, cognitive function, changes in BPSD symptoms, clinical global impression and quality of life were analysed. For assessing harm, we assessed adverse events, drop-outs as a proxy for treatment tolerability and death. Results were analysed according to Cochrane standards and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 45,045 search results, 38,447 abstracts and 187 full texts were screened, and finally, 10 RCTs were included in the systematic review. Selected articles evaluated pharmacotherapy with acetylcholinesterase-inhibitors (AChEI), anticonvulsants, antidepressants and antipsychotics. Studies of AChEIs suggested that patients with significant functional impairments had slight but significant improvements in cognition and that AChEIs were generally well tolerated. Studies of antidepressants did not show significant improvements in depressive symptoms. Antipsychotics and anticonvulsants showed small effects on some BPSD items but also higher rates of adverse events. However, due to the very small number of identified trials, the quality of evidence for all outcomes was low to very low.<\/jats:p>\n                <jats:p>Overall, the small number of eligible studies demonstrates that significantly functional impaired older patients have not been adequately taken into consideration in most clinical trials investigating drug therapy of AD and BPSD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Due to lack of evidence, it is not possible to give specific recommendations for drug therapy of AD and BSPD in frail older patients or older patients with significant functional impairments. Therefore, clinical trials focussing on frail older adults are urgently required. A standardized approach to physical frailty in future clinical studies is highly desirable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00867-8","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T20:02:31Z","timestamp":1626465751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy and safety of pharmacotherapy for Alzheimer\u2019s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials"],"prefix":"10.1186","volume":"13","author":[{"given":"M.","family":"Seibert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"M\u00fchlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Voigt-Radloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brefka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sch\u00f6nfeldt-Lecuona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kl\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. F.","family":"von Arnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"issue":"9868","key":"867_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Olde Rikkert M, Rockwood K. Frailty in older people. Lancet. 2013;381(9868):752\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(12)62167-9.","journal-title":"Lancet"},{"key":"867_CR2","volume-title":"World report on ageing and health","author":"Word Health Organization","year":"2015","unstructured":"Word Health Organization. World report on ageing and health. 2015; Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/186463\/1\/9789240694811_eng.pdf. Accessed 18.12.2017."},{"issue":"8","key":"867_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/j.1532-5415.2012.04054.x","volume":"60","author":"RM Collard","year":"2012","unstructured":"Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487\u201392. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04054.x.","journal-title":"J Am Geriatr Soc"},{"key":"867_CR4","doi-asserted-by":"publisher","unstructured":"Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8). https:\/\/doi.org\/10.1101\/cshperspect.a006239.","DOI":"10.1101\/cshperspect.a006239"},{"issue":"7","key":"867_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jclinepi.2009.09.007","volume":"63","author":"F Landi","year":"2010","unstructured":"Landi F, Liperoti R, Russo A, Capoluongo E, Barillaro C, Pahor M, et al. Disability, more than multimorbidity, was predictive of mortality among older persons aged 80\u2009years and older. J Clin Epidemiol. 2010;63(7):752\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.09.007.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"867_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamasurg.2016.4219","volume":"152","author":"DE Hall","year":"2017","unstructured":"Hall DE, Arya S, Schmid KK, Carlson MA, Lavedan P, Bailey TL, et al. Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365\u2009Days. JAMA Surg. 2017;152(3):233\u201340.","journal-title":"JAMA Surg"},{"issue":"2","key":"867_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ageing\/afx162","volume":"47","author":"G Kojima","year":"2018","unstructured":"Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47(2):193\u2013200.","journal-title":"Age Ageing"},{"issue":"3","key":"867_CR8","doi-asserted-by":"publisher","first-page":"e33559","DOI":"10.1371\/journal.pone.0033559","volume":"7","author":"C Konrat","year":"2012","unstructured":"Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. Plos One. 2012;7(3):e33559.","journal-title":"Plos One"},{"issue":"5","key":"867_CR9","doi-asserted-by":"publisher","first-page":"e0124500","DOI":"10.1371\/journal.pone.0124500","volume":"10","author":"A Leinonen","year":"2015","unstructured":"Leinonen A, Koponen M, Hartikainen S. Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors. Plos One. 2015;10(5):e0124500. https:\/\/doi.org\/10.1371\/journal.pone.0124500.","journal-title":"Plos One"},{"key":"867_CR10","doi-asserted-by":"crossref","unstructured":"Schoenmaker N, Van Gool W,A. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol. 2004;3(10):627-630.","DOI":"10.1016\/S1474-4422(04)00884-1"},{"key":"867_CR11","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Studies in Support of Special Populations: Geriatrics E7. 24.06.1993; Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E7\/Step4\/E7_Guideline.pdf. Accessed 26.12.2017."},{"key":"867_CR12","volume-title":"Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2018","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials.2018; Available at: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical_en.pdf. Accessed 08.09.2018."},{"issue":"4","key":"867_CR13","first-page":"489","volume":"12","author":"S Singh","year":"2014","unstructured":"Singh S, Bajorek B. Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy. Pharm Pract. 2014;12(4):489.","journal-title":"Pharm Pract"},{"key":"867_CR14","doi-asserted-by":"publisher","unstructured":"Kroger E, Mouls M, Wilchesky M, Berkers M, Carmichael P-, van Marum R, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16\u2009years of individual case safety reports from VigiBase. Ann Pharmacother 2015;49(11):1197-1206, doi: https:\/\/doi.org\/10.1177\/1060028015602274.","DOI":"10.1177\/1060028015602274"},{"issue":"8","key":"867_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843\u201353. https:\/\/doi.org\/10.1016\/S0531-5565(03)00133-5.","journal-title":"Exp Gerontol"},{"issue":"3","key":"867_CR16","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201356. https:\/\/doi.org\/10.1093\/gerona\/56.3.M146.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"867_CR17","doi-asserted-by":"crossref","unstructured":"Walston J, Hadley E, Ferrucci L, Guralnik J, Newman A, Studenski S, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society\/National Institute on aging research conference on frailty in older adults. J Am Geriatr Soc 2006 06\/01; 2020\/06;54(6):991-1001.","DOI":"10.1111\/j.1532-5415.2006.00745.x"},{"issue":"4","key":"867_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/00002512-200017040-00005","volume":"17","author":"K Rockwood","year":"2000","unstructured":"Rockwood K, Hogan D, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs Aging. 2000;17(4):295\u2013302.","journal-title":"Drugs Aging"},{"issue":"3 Suppl","key":"867_CR19","first-page":"1","volume":"15","author":"DB Hogan","year":"2003","unstructured":"Hogan DB, MacKnight C, Bergman H. Canadian Initiative on Frailty and Aging. Models, definitions, and criteria of frailty. Aging Clin Exp Res. 2003;15(3 Suppl):1\u201329.","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"867_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","volume":"62","author":"K Rockwood","year":"2007","unstructured":"Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722\u20137. https:\/\/doi.org\/10.1093\/gerona\/62.7.722.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"867_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/01.wnl.0000324864.81179.6a","volume":"71","author":"AS Buchman","year":"2008","unstructured":"Buchman AS, Schneider JA, Leurgans S, Bennett DA. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology. 2008;71(7):499\u2013504. https:\/\/doi.org\/10.1212\/01.wnl.0000324864.81179.6a.","journal-title":"Neurology"},{"issue":"1","key":"867_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000353859","volume":"60","author":"J Kulmala","year":"2014","unstructured":"Kulmala J, Nykanen I, Manty M, Hartikainen S. Association between frailty and dementia: a population-based study. Gerontology. 2014;60(1):16\u201321. https:\/\/doi.org\/10.1159\/000353859.","journal-title":"Gerontology"},{"issue":"9","key":"867_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10072-013-1290-3","volume":"34","author":"A Clodomiro","year":"2013","unstructured":"Clodomiro A, Gareri P, Puccio G, Frangipane F, Lacava R, Castagna A, et al. Somatic comorbidities and Alzheimer's disease treatment. Neurol Sci. 2013;34(9):1581\u20139. https:\/\/doi.org\/10.1007\/s10072-013-1290-3.","journal-title":"Neurol Sci"},{"issue":"5","key":"867_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/psy.0b013e318068de1d","volume":"69","author":"AS Buchman","year":"2007","unstructured":"Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA. Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. Psychosom Med. 2007;69(5):483\u20139. https:\/\/doi.org\/10.1097\/psy.0b013e318068de1d.","journal-title":"Psychosom Med"},{"issue":"10","key":"867_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s12603-011-0066-9","volume":"15","author":"A Mitnitski","year":"2011","unstructured":"Mitnitski A, Fallah N, Rockwood MRH, Rockwood K. Transitions in cognitive status in relation to frailty in older adults: a comparison of three frailty measures. J Nutr Health Aging. 2011;15(10):863\u20137. https:\/\/doi.org\/10.1007\/s12603-011-0066-9.","journal-title":"J Nutr Health Aging"},{"issue":"12","key":"867_CR26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp-2016-313660","volume":"87","author":"P Soysal","year":"2016","unstructured":"Soysal P, Isik AT, Stubbs B, Solmi M, Volpe M, Luchini C, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(12):1368\u201374. https:\/\/doi.org\/10.1136\/jnnp-2016-313660.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"867_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"key":"867_CR28","doi-asserted-by":"publisher","unstructured":"Sugimoto T, Ono R, Kimura A, Saji N, Niida S, Toba K, et al. Physical Frailty Correlates With Behavioral and Psychological Symptoms of Dementia and Caregiver Burden in Alzheimer\u2019s Disease. J Clin Psychiatry. 2018;79:e1\u20137. https:\/\/doi.org\/10.4088\/JCP.17m11991.","DOI":"10.4088\/JCP.17m11991"},{"key":"867_CR29","doi-asserted-by":"crossref","unstructured":"Boy\u00e9 NDA, Van Lieshout EMM, Van Beeck EF, Hartholt KA, Van der Cammen TJM, Patka P. The impact of falls in the elderly. Trauma 2013 01\/01; 2019\/10;15(1):29-35.","DOI":"10.1177\/1460408612463145"},{"key":"867_CR30","unstructured":"National Institute for Health and Care Excellence. NICE guideline Dementia: assessment, management and support for people living with dementia and their carers. 2018; Available at: https:\/\/www.nice.org.uk\/guidance\/ng97. Accessed 20.05.2021."},{"key":"867_CR31","doi-asserted-by":"crossref","unstructured":"Cerreta F, Eichler H-, Rasi G. Drug Policy for an Aging Population - The European Medicines Agency\u2019s Geriatric Medicines Strategy. N Engl J Med 2012 11\/22; 2017\/12;367(21):1972-1974.","DOI":"10.1056\/NEJMp1209034"},{"issue":"6","key":"867_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00019442-200506000-00005","volume":"13","author":"IS Shin","year":"2005","unstructured":"Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(6):469\u201374. https:\/\/doi.org\/10.1097\/00019442-200506000-00005.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"22","key":"867_CR33","first-page":"2716","volume":"163","author":"DM Fick","year":"2003","unstructured":"Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a us consensus panel of experts. Intemed. 2003;163(22):2716\u201324.","journal-title":"Intemed"},{"issue":"31-32","key":"867_CR34","first-page":"543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann P. Potentially inappropriate medications in the elderly: the PRISCUS list. Deutsches \u00c4rzteblatt Int. 2010;107(31-32):543\u201351.","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"867_CR35","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Med 2009;6(7)(5\/9\/2017).","DOI":"10.1371\/journal.pmed.1000097"},{"key":"867_CR36","unstructured":"Higgins J, Green S, The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011; Available at: www.handbook.cochrane.org. Accessed 09.05.2017."},{"key":"867_CR37","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"867_CR38","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: American Psychiatric Association; 2000."},{"key":"867_CR39","volume-title":"The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. 1992."},{"issue":"7","key":"867_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"issue":"2","key":"867_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jamda.2018.11.008","volume":"20","author":"S Brefka","year":"2019","unstructured":"Brefka S, Dallmeier D, Muehlbauer V, von Arnim CAF, Bollig C, Onder G, et al. A proposal for the retrospective identification and categorization of older people with functional impairments in scientific studies - recommendations of the Medication and Quality of Life in Frail Older Persons (MedQoL) Research Group. J Am Med Direct Assoc. 2019;20(2):138\u201346.","journal-title":"J Am Med Direct Assoc"},{"key":"867_CR42","unstructured":"Seibert M. Anwendbarkeit von medikament\u00f6ser Therapie der Alzheimer Demenz sowie behavioraler und psychologischer Symptome der Demenz (BPSD) bei funktionell beeintr\u00e4chtigten Patienten (\u201efrail elderly\u201c): Eine systematische \u00dcbersichtsarbeit (Protokoll). 2017."},{"key":"867_CR43","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Abschlussbericht A05-19A: Cholinesterasehemmer bei Alzheimer Demenz. 2007; Available at: https:\/\/www.iqwig.de\/download\/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf. Accessed 26.07.2018."},{"key":"867_CR44","volume-title":"Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease","author":"Committee for Medicinal Products for Human Use","year":"2018","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. 2018; Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf. Accessed 21.08.2019."},{"issue":"1","key":"867_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0749-0690(18)30494-4","volume":"8","author":"DM Buchner","year":"1992","unstructured":"Buchner DM, Wagner EH. Preventing Frail Health. Clin Geriatr Med. 1992;8(1):1\u201318.","journal-title":"Clin Geriatr Med"},{"key":"867_CR46","unstructured":"Covidence, Cochrane Collaboration, Instituto de Efectividad Clinica Y Sanitaria (EROS), Alfred Hospital Melbourne. Covidence. 2017; Available at: https:\/\/www.covidence.org\/. Accessed 29.08.2017."},{"key":"867_CR47","volume-title":"Data collection form. EPOC Resources for review authors, 2017","author":"Cochrane Effective Practice and Organisation of Care (EPOC)","year":"2017","unstructured":"Cochrane Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC Resources for review authors, 2017. 2017; Available at: http:\/\/epoc.cochrane.org\/epoc-specific-resources-review-authors. Accessed 19.05.2018."},{"issue":"oct18 2","key":"867_CR48","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"867_CR49","volume-title":"Review Manager (RevMan) 5.3","author":"The Nordic Cochrane Centre","year":"2014","unstructured":"The Nordic Cochrane Centre. Review Manager (RevMan) 5.3. 2014."},{"issue":"7650","key":"867_CR50","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"7454","key":"867_CR51","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"BMJ"},{"key":"867_CR52","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"H Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013; Available at: gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html. Accessed 20.07.19."},{"key":"867_CR53","unstructured":"Cohen J. 2.2.3 \u201cSmall,\u201d \u201cMedium,\u201d and \u201cLarge\u201d d Values. In: Lawrence Erlbaum Associates H, editor. Statistical Power Analysis for the Behavioral Sciences. 2nd ed.; 1988. p. 24-26."},{"issue":"12","key":"867_CR54","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin Epidemiol. 2011;64(12):1283\u201393. https:\/\/doi.org\/10.1016\/j.jclinepi.2011.01.012.","journal-title":"J Clin Epidemiol"},{"key":"867_CR55","unstructured":"Evidence Prime I, McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. 2015."},{"issue":"2","key":"867_CR56","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1017\/S104161020100761X","volume":"13","author":"GM Petracca","year":"2001","unstructured":"Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer\u2019s disease. Int Psychogeriatr. 2001;13(2):233\u201340. https:\/\/doi.org\/10.1017\/S104161020100761X.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"867_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","volume":"8","author":"A Burns","year":"2009","unstructured":"Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Fr\u00f6lich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(08)70261-8.","journal-title":"Lancet Neurol"},{"issue":"12","key":"867_CR58","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","volume":"49","author":"PN Tariot","year":"2001","unstructured":"Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2001.49266.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"867_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1176\/jnp.8.3.270","volume":"8","author":"G Petracca","year":"1996","unstructured":"Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):270\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"867_CR60","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/00019442-200111000-00008","volume":"9","author":"JT Olin","year":"2001","unstructured":"Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):400\u20135. https:\/\/doi.org\/10.1097\/00019442-200111000-00008.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"867_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","volume":"9","author":"AP Porsteinsson","year":"2001","unstructured":"Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9(1):58\u201366. https:\/\/doi.org\/10.1097\/00019442-200102000-00009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"867_CR62","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1532-5415.1994.tb06982.x","volume":"42","author":"PN Tariot","year":"1994","unstructured":"Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42(11):1160\u20136. https:\/\/doi.org\/10.1111\/j.1532-5415.1994.tb06982.x.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"867_CR63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1176\/ajp.155.1.54","volume":"155","author":"PN Tariot","year":"1998","unstructured":"Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54\u201361. https:\/\/doi.org\/10.1176\/ajp.155.1.54.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"867_CR64","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","volume":"14","author":"PN Tariot","year":"2006","unstructured":"Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767\u201376. https:\/\/doi.org\/10.1097\/01.JGP.0000196628.12010.35.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"867_CR65","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/JCP.0b013e31829798d5","volume":"33","author":"M Teranishi","year":"2013","unstructured":"Teranishi M, Kurita M, Nishino S, Takeyoshi K, Numata Y, Sato T, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol. 2013;33(5):600\u20137. https:\/\/doi.org\/10.1097\/JCP.0b013e31829798d5.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"867_CR66","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/ptr.3146","volume":"24","author":"S de Caires","year":"2010","unstructured":"de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: a review. Phytother Res. 2010;24(9):1265\u201370. https:\/\/doi.org\/10.1002\/ptr.3146.","journal-title":"Phytother Res"},{"issue":"4","key":"867_CR67","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.neuroscience.2009.02.004","volume":"159","author":"Z Kawakami","year":"2009","unstructured":"Kawakami Z, Kanno H, Ueki T, Terawaki K, Tabuchi M, Ikarashi Y, et al. Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience. 2009;159(4):1397\u2013407. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.02.004.","journal-title":"Neuroscience"},{"issue":"3","key":"867_CR68","first-page":"411","volume":"27","author":"C Swinne","year":"1998","unstructured":"Swinne C, Cornette P, Schoevaerdts D, Latteur V, Melon C. Frailty in the medical literature. Ageing. 1998;27(3):411\u20133.","journal-title":"Ageing"},{"issue":"7267","key":"867_CR69","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1136\/bmj.321.7267.992","volume":"321","author":"A Bayer","year":"2000","unstructured":"Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ. 2000;321(7267):992\u20133.","journal-title":"BMJ"},{"key":"867_CR70","doi-asserted-by":"crossref","unstructured":"Hempenius L, Slaets JPJ, Boelens MAM, van Asselt DZB, de Bock GH, Wiggers T, et al. Inclusion of frail elderly patients in clinical trials: Solutions to the problems. J Geriatr Oncol. 2013 01\/01; 2019\/07;4(1):26-31.","DOI":"10.1016\/j.jgo.2012.08.004"},{"issue":"6","key":"867_CR71","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejim.2005.08.001","volume":"16","author":"HU Rehman","year":"2005","unstructured":"Rehman HU. Under-representation of the elderly in clinical trials. Eur J Intern Med. 2005;16(6):385\u20136.","journal-title":"Eur J Intern Med"},{"key":"867_CR72","doi-asserted-by":"publisher","unstructured":"Birks JS. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1. https:\/\/doi.org\/10.1002\/14651858.CD005593.","DOI":"10.1002\/14651858.CD005593"},{"key":"867_CR73","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Abschlussbericht A05-19A: Cholinesterasehemmer bei Alzheimer Demenz. 2007; Available at: https:\/\/www.iqwig.de\/download\/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf. Accessed 18.07.2018."},{"key":"867_CR74","doi-asserted-by":"crossref","unstructured":"Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006;1.","DOI":"10.1002\/14651858.CD001190.pub2"},{"issue":"5","key":"867_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","volume":"69","author":"SE Black","year":"2007","unstructured":"Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459.","journal-title":"Neurology"},{"issue":"9516","key":"867_CR76","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"B Winblad","year":"2006","unstructured":"Winblad B, Kilander L, Eriksson S, Minthon L, B\u00e5tsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study. Lancet (london). 2006;367(9516):1057\u201365.","journal-title":"Lancet (london)"},{"key":"867_CR77","doi-asserted-by":"crossref","unstructured":"Blanco-Silvente L, Castells X, Saez M, Barcelo MA, Garre-Olmo J, Vilalta-Franch J, et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. ijnp 2017 02\/13; 9\/26;20(7):519-528.","DOI":"10.1093\/ijnp\/pyx012"},{"issue":"9","key":"867_CR78","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/jgs.15415","volume":"66","author":"AT Isik","year":"2018","unstructured":"Isik AT, Soysal P, Stubbs B, Solmi M, Basso C, Maggi S, et al. Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review. J Am Geriatr Soc. 2018;66(9):1805\u201311.","journal-title":"J Am Geriatr Soc"},{"key":"867_CR79","doi-asserted-by":"crossref","unstructured":"Monacelli F, Rosa GM. Cholinesterase inhibitors: cardioprotection in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis, 42 2014;4:1071-1077.","DOI":"10.3233\/JAD-141089"},{"issue":"1","key":"867_CR80","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.arr.2011.07.002","volume":"11","author":"M Azermai","year":"2012","unstructured":"Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev. 2012;11(1):78\u201386.","journal-title":"Ageing Res Rev"},{"key":"867_CR81","doi-asserted-by":"crossref","unstructured":"Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018;8.","DOI":"10.1002\/14651858.CD003944.pub2"},{"key":"867_CR82","doi-asserted-by":"crossref","unstructured":"Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 2011 05\/01; 2019\/09;26(3):169-183.","DOI":"10.1177\/1533317511402051"},{"key":"867_CR83","doi-asserted-by":"crossref","unstructured":"Thompson S, Herrmann N, Rapoport MJ, Lanct\u00f4t K,L. Efficacy and safety of antidepressants for treatment of depression in Alzheimer\u2019s disease: a metaanalysis. Can J Psychiatry 2007 04\/01; 2019\/09;52(4):248-255.","DOI":"10.1177\/070674370705200407"},{"issue":"4","key":"867_CR84","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000121334","volume":"25","author":"E Mossello","year":"2008","unstructured":"Mossello E, Boncinelli M, Caleri V, Cavallini MC, Palermo E, Di Bari M, et al. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer\u2019s disease? Dement Geriatr Cogn Disord. 2008;25(4):372\u20139. https:\/\/doi.org\/10.1159\/000121334.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"867_CR85","doi-asserted-by":"publisher","first-page":"10.02.2020-17","DOI":"10.1186\/1750-1326-5-10","volume":"5","author":"M Aboukhatwa","year":"2010","unstructured":"Aboukhatwa M, Dosanjh L, Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer\u2019s disease. Mol Neurodegen. 2010;5:10.02.2020-17.","journal-title":"Mol Neurodegen"},{"key":"867_CR86","doi-asserted-by":"crossref","unstructured":"Baillon SF, Narayana U, Luxenberg JS, Clifton AV. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2018;10.","DOI":"10.1002\/14651858.CD003945.pub4"},{"issue":"5","key":"867_CR87","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrneurol.2009.39","volume":"5","author":"CG Ballard","year":"2009","unstructured":"Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245\u201355.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"867_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.kjms.2011.10.025","volume":"28","author":"Y Yeh","year":"2012","unstructured":"Yeh Y, Ouyang W. Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. Kaohsiung J Med Sci. 2012;28(4):185\u201393.","journal-title":"Kaohsiung J Med Sci"},{"issue":"6","key":"867_CR89","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385\u2013407.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"867_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","volume":"15","author":"AR Moore","year":"1999","unstructured":"Moore AR, O\u2019Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15\u201328.","journal-title":"Drugs Aging"},{"issue":"13","key":"867_CR91","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Truran D, Mai JT, Langbaum JBS, Aisen PS, Cummings JL, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77(13):1263.","journal-title":"Neurology"},{"key":"867_CR92","doi-asserted-by":"crossref","unstructured":"Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3.","DOI":"10.1002\/14651858.CD003945.pub3"},{"key":"867_CR93","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eplepsyres.2017.10.022","volume":"138","author":"Y Haasum","year":"2017","unstructured":"Haasum Y, Johnell K. Use of antiepileptic drugs and risk of falls in old age: a systematic review. Epilepsy Res. 2017;138:98\u2013104.","journal-title":"Epilepsy Res"},{"issue":"2","key":"867_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1715163517690744","volume":"150","author":"M Maximos","year":"2017","unstructured":"Maximos M, Chang F, Patel T. Risk of falls associated with antiepileptic drug use in ambulatory elderly populations: a systematic review. Can Pharm J. 2017;150(2):101\u201311.","journal-title":"Can Pharm J"},{"key":"867_CR95","volume-title":"Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine","author":"The National Institute for Health and Care Excellence (NICE)","year":"2015","unstructured":"The National Institute for Health and Care Excellence (NICE). Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine. 2015; Available at: https:\/\/www.nice.org.uk\/advice\/esuom40\/chapter\/Full-evidence-summary. Accessed 11.10.2019."},{"issue":"11","key":"867_CR96","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/JGP.0b013e31813547ca","volume":"15","author":"J Hollis","year":"2007","unstructured":"Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic Medication Dispensing and Risk of Death in Veterans and War Widows 65\u2009Years and Older. Am J Geriatr Psychiatry. 2007;15(11):932\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"867_CR97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1017\/S1041610207006540","volume":"20","author":"S Konovalov","year":"2008","unstructured":"Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293\u2013308. https:\/\/doi.org\/10.1017\/S1041610207006540.","journal-title":"Int Psychogeriatr"},{"key":"867_CR98","doi-asserted-by":"crossref","unstructured":"Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;1.","DOI":"10.1002\/14651858.CD003476.pub2"},{"key":"867_CR99","doi-asserted-by":"publisher","unstructured":"Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;2. https:\/\/doi.org\/10.1002\/14651858.CD003945.","DOI":"10.1002\/14651858.CD003945"},{"issue":"7496","key":"867_CR100","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"C Ballard","year":"2005","unstructured":"Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.","journal-title":"BMJ"},{"issue":"7076","key":"867_CR101","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bmj.314.7076.266","volume":"314","author":"R McShane","year":"1997","unstructured":"McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997;314(7076):266.","journal-title":"BMJ"},{"issue":"3","key":"867_CR102","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191\u2013210.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"867_CR103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jnnp.2006.094342","volume":"78","author":"G Livingston","year":"2007","unstructured":"Livingston G, Walker AE, Katona CLE, Cooper C. Antipsychotics and cognitive decline in Alzheimer\u2019s disease: the LASER-Alzheimer\u2019s disease longitudinal study. J Neurol Neurosurg Psychiatr. 2007;78(1):25\u20139.","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"2","key":"867_CR104","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/jnnp.69.2.172","volume":"69","author":"RS Wilson","year":"2000","unstructured":"Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. Hallucinations, delusions, and cognitive decline in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatr. 2000;69(2):172.","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"2","key":"867_CR105","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/JGP.0b013e3181e446c8","volume":"19","author":"JE Emanuel","year":"2011","unstructured":"Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, Demichele-Sweet MAA, et al. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry. 2011;19(2):160\u20138. https:\/\/doi.org\/10.1097\/JGP.0b013e3181e446c8.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"867_CR106","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00019442-200409000-00009","volume":"12","author":"G Suh","year":"2004","unstructured":"Suh G, Son HG, Ju Y, Jcho KH, Yeon BK, Shin YM, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. 2004;12(5):509\u201316.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"867_CR107","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/gps.504","volume":"16","author":"WC Chan","year":"2001","unstructured":"Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16(12):1156\u201362. https:\/\/doi.org\/10.1002\/gps.504.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"867_CR108","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jagp.2013.06.007","volume":"22","author":"EM Langballe","year":"2014","unstructured":"Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selb\u00e6k G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321\u201331.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"867_CR109","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/11319120-000000000-00000","volume":"33","author":"E Sacchetti","year":"2010","unstructured":"Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs. Drug Saf. 2010;33(4):273\u201388.","journal-title":"Drug Saf"},{"issue":"15","key":"867_CR110","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementiameta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u201343.","journal-title":"JAMA"},{"issue":"9","key":"867_CR111","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/156720512803569037","volume":"9","author":"V Gardette","year":"2012","unstructured":"Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, et al. Antipsychotic use and mortality risk in community-dwelling Alzheimer\u2019s disease patients: evidence for a role of dementia severity. Curr Alzheimer Res. 2012;9(9):1106\u201316. https:\/\/doi.org\/10.2174\/156720512803569037.","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"867_CR112","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1176\/appi.ajp.2013.12081046","volume":"170","author":"OL Lopez","year":"2013","unstructured":"Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer\u2019s disease. Am J Psychiatry. 2013;170(9):1051\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.2013.12081046.","journal-title":"Am J Psychiatry"},{"key":"867_CR113","doi-asserted-by":"crossref","unstructured":"The 2019 American Geriatrics Society Beers Criteria (R) Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019. 67(4):674-694.","DOI":"10.1111\/jgs.15767"},{"key":"867_CR114","unstructured":"Deuschl G, Maier W. S3-Leitlinie Demenzen. Deutsche Gesellschaft f\u00fcr Neurologie, Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 2016."},{"key":"867_CR115","first-page":"CD007726","volume":"3","author":"E Van Leeuwen","year":"2018","unstructured":"Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:CD007726.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"867_CR116","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","volume":"8","author":"C Ballard","year":"2009","unstructured":"Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(08)70295-3.","journal-title":"Lancet Neurol"},{"issue":"5","key":"867_CR117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/MCO.0000000000000202","volume":"18","author":"RW Bohannon","year":"2015","unstructured":"Bohannon RW. Muscle strength: clinical and prognostic value of hand-grip dynamometry. Curr Opin Clin Nutr Metab Care. 2015;18(5):465\u201370. https:\/\/doi.org\/10.1097\/MCO.0000000000000202.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"867_CR118","doi-asserted-by":"publisher","first-page":"M85","DOI":"10.1093\/geronj\/49.2.M85","volume":"49","author":"JM Guralnik","year":"1994","unstructured":"Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85\u201394. https:\/\/doi.org\/10.1093\/geronj\/49.2.M85.","journal-title":"J Gerontol"},{"key":"867_CR119","doi-asserted-by":"crossref","unstructured":"Binotto MA, Lenardt MH, Rodr\u00edguez-Mart\u00ednez MDC. Physical frailty and gait speed in community elderly: a systematic review. Rev Esc Enferm USP 2018;52:e03392-220X2017028703392.","DOI":"10.1590\/s1980-220x2017028703392"},{"key":"867_CR120","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"key":"867_CR121","doi-asserted-by":"crossref","unstructured":"Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, et al. European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open. 2016;6(7):e011584.","DOI":"10.1136\/bmjopen-2016-011584"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T21:04:23Z","timestamp":1626469463000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00867-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"05.07.2017, Ethics committee of the University of Ulm, Germany. Anonymized data only was used. No further approval required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CvA received honoraria from serving on the scientific advisory board of Biogen, Roche, and Dr. Willmar Schwabe GmbH &Co. KG and has received funding for travel and speaker honoraria from Lilly GmbH, Daiichi Sankyo, Biogen, Roche diagnostics AG and Dr. Willmar Schwabe GmbH &Co. KG and has received research support from Roche diagnostics AG. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}